✦ LIBER ✦

The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

✍ Scribed by Ayalew Tefferi; Terra L. Lasho; Susan M. Schwager; David P. Steensma; Ruben A. Mesa; Chin-Yang Li; Martha Wadleigh; D. Gary Gilliland

Book ID: 108673460
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 116 KB
Volume: 131
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2005.05776.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Presence of JAK2 V617F tyrosine kinase m

Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia

✍ Lea, N C; Lim, Z; Westwood, N B; Arno, M J; Gäken, J; Mohamedali, A; Mufti, G J 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 125 KB

Eradication of JAK2 V617F mutation after

Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia

✍ Fiorini, A; Reddiconto, G; Farina, G; Marietti, S; Palladino, M; Chiusolo, P; Le 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 100 KB

Clearance of the Janus kinase 2 (JAK2) V

Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia

✍ Guillermo J. Ruiz-Argüelles; Javier Garcés-Eisele; Virginia Reyes-Núñez; Guiller 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

Janus kinase 2 (V617F) mutation status,

Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia

✍ Mesa, R A; Tefferi, A; Lasho, T S; Loegering, D; McClure, R F; Powell, H L; Dai, 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 283 KB

Correlations of JAK2–V617F mutation with

Correlations of JAK2–V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders

✍ Matthaios Speletas; Eirini Katodritou; Chrisoula Daiou; Eudokia Mandala; Emmanou 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 212 KB

Recently, the acquired mutation JAK2-V617F has been described in the majority of patients with myeloproliferative disorders (MPDs). In this study we evaluated its clinical and laboratory correlates in 166 patients with MPDs. The mutation was detected by allele-specific PCR in 119 patients: 81.4% (35

The JAK2 V617F tyrosine kinase mutation

The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients

✍ Ohyashiki, K; Aota, Y; Akahane, D; Gotoh, A; Miyazawa, K; Kimura, Y; Ohyashiki, 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 109 KB